BioMarin Pharma Reaches Agreement On Reimbursement Amount For ROCTAVIAN In Germany finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
BioMarin Pharma (BMRN) Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN for Severe Hemophilia A in Germany streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
ROCTAVIAN is First Gene Therapy for Hemophilia to Receive Approved Federal Price in Germany
SAN RAFAEL, Calif., Nov. 28, 2023 /PRNewswire/ BioMarin Pharmaceutical Inc. , a global biotechnology.
BioMarin Pharmaceutical said
on Tuesday it will price its therapy for severe hemophilia A at
28,933.53 euros per vial for insurers covering a
majority of the population in Germany, Europe s.